Pacira BioSciences (NASDAQ: PCRX) has announced a significant $300 million share repurchase program, receiving support from DOMA Perpetual Capital Management, which owns 4.2% of the company's outstanding shares.
The initiative, representing the largest buyback in Pacira's history, comes alongside a new emphasis on increasing pre-tax net income margins. DOMA Perpetual views these moves as reflecting Pacira's strong financial position and the Board's commitment to disciplined capital allocation.
According to Pedro Escudero, CEO of DOMA Perpetual, Pacira has entered a period of rapid growth, with scaling earnings and free cash flow enabling capital returns while maintaining investment in growth.
DOMA Perpetual believes the stock is currently undervalued relative to both its historical average and future growth potential.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.